Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A Malaysian perspective

Ahmad Radzi, Fabian Wei Luen Lee

Abstract


The incidence of postmenopausal, hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer is high in Malaysia. Despite the high incidence and other challenges in the local settings, there is an unmet need for optimal treatment strategies for the management of these patients. The current article includes a comprehensive review of the key clinical evidences on the management of postmenopausal women with HR+, HER2– or unknown HER2 status advanced breast cancer, with focus on the emerging role of fulvestrant and novel combinations of hormone and targeted therapies, in improving the survival outcomes. All the evidences have been rated based on the GRADE criteria by local Oncology experts through a consensus opinion, and treatment-sequencing strategies have been proposed for the optimal first- and second-line management of this patient population. The proposed strategies may serve as a useful guide to the clinicians for optimizing the treatment of these patients. Optimization of treatment in the local context may be further improved, by addressing the immediate challenges, related to availability/ access to emerging treatments, enhancement of disease awareness and early diagnosis. Detection of driver mutations, and reliable biomarkers for predicting treatment outcomes may serve as a step ahead in the management of these patients in future.

Keywords


postmenopausal advanced breast cancer; HR-positive; HER2-negative; treatment-sequencing strategies

Full Text:

PDF

References


Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359–E386. doi: 10.1002/ijc.29210.

Manan AA, et al. Malaysian National Cancer Registry report (2007–2011); June 2015. Available from: http://nci.moh.gov.my/index.php/en/announcement/340-malaysian-national-cancer-registry-report-2007–2011.

Azizah AM, Devaraj T, Bina RS, Yusuff N, Mansoor N, Shuib N. Penang Cancer Registry Report 2004–2008. Available from: http://www.ncsmpenang.org/storage/upload/ncsm/files/PCR20042008(1).pdf.

Yip CH, Bhoo Pathy N, Teo SH. A review of breast cancer research in malaysia. Med J Malaysia 2014; 69(Suppl A): 8–22.

Ng CH, Pathy NB, Taib NA, Teh YC, Mun KS, et al. Comparison of breast cancer in Indonesia and Malaysia--a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. Asian Pac J Cancer Prev 2011; 12(11): 2943–2946.

Devi CR, Tang TS, Corbex M. Incidence and risk factors for breast cancer subtypes in three distinct Southeast Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. Int J Cancer 2012; 131(12): 2869–2877. doi: 10.1002/ijc.27527.

Yu FQ, Murugiah MK, Khan AH, Mehmood T. Meta-synthesis exploring barriers to health seeking behaviour among Malaysian breast cancer patients. Asian Pac J Cancer Prev 2015; 16(1): 145–152.

Khan TM, Leong JP, Ming LC, Khan AH. Association of knowledge and cultural perceptions of Malaysian women with delay in diagnosis and treatment of breast cancer: A systematic review. Asian Pac J Cancer Prev 2015; 16(13): 5349–5357.

Norsa'adah B, Rampal KG, Rahmah MA, Naing NN, Biswal BM. Diagnosis delay of breast cancer and its associated factors in Malaysian women. BMC Cancer 2011; 11: 141. doi: 10.1186/1471-2407-11-141.

Yip CH, Taib NA, Mohamed I. Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev 2006; 7: 369–374.

Saxena N, Hartman M, Bhoo-Pathy N, Lim JN, Aw TC, et al. Breast cancer in South East Asia: Comparison of presentation and outcome between a middle income and a high income country. World J Surg 2012; 36(12): 2838–2846. doi: 10.1007/s00268-012-1746-2.

Bhoo-Pathy N, Verkooijen HM, Tan EY, Miao H, Taib NAM, et al. Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting. Sci Rep 2015; 5: 16252. doi: 10.1038/srep16252.

Ibrahim NI, Dahlui M, Aina EN, Al-Sadat N. Who are the breast cancer survivors in Malaysia? Asian Pac J Cancer Prev 2012; 13(5): 2213–2218.

Fan L, Goss PE, Strasser-Weippl K. Current Status and Future Projections of Breast Cancer in Asia. Breast Care (Basel) 2015; 10: 372–378. doi: 10.1159/000441818.

Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol 2012; 23: x243–248. doi: 10.1093/annonc/mds305.

Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, et al. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. Eur J Cancer 2013; 49(14): 2986–2994. doi: 10.1016/j.ejca.2013.05.006.

Untch M, Harbeck N, Huober J, von Minckwitz G, Gerber B, et al. Primary therapy of patients with early breast cancer: Evidence, controversies, consensus: Opinions of German specialists to the 14th St. Gallen international breast cancer conference 2015 (Vienna 2015). Geburtshilfe Frauenheilkd 2015; 75(6): 556–565.

Dixon JM. Endocrine Resistance in Breast Cancer. New J Sc 2014. doi: 10.1155/2014/390618.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v8–v30. doi: 10.1093/annonc/mdv298.

Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J Clin Oncol 2007; 25(19): 2664–2670. doi: 10.1200/JCO.2006.08.8054.

Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006; 17: vii10–vii14. doi: 10.1093/annonc/mdl941.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28(3): 509–518. doi: 10.1200/JCO.2009.23.1274.

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11(12): 1135–1141. doi: 10.1016/S1470-2045(10)70257-6.

van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 2011; 377(9762): 321–331. doi: 10.1016/S0140-6736(10)62312-4.

Gradishar W, Salerno KE. NCCN Guidelines Update: Breast Cancer. J Natl Compr Canc Netw 2016; 14: 641–644.

Knauer M, Gruber C, Dietze O, Greil R, Stoger H, et al. Abstract S2–06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 study. Cancer Research 2015; 75(9). doi: 10.1158/1538-7445.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years afterdiagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381(9869): 805–816. doi: 10.1016/S0140-6736(12)61963-1.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375(16): 209–219. doi: 10.1056/NEJMc1610719.

Cardoso F, Costa A, Senkus E, Aapro M, André F, et al. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28(12): 3111. doi: 10.1093/annonc/mdx036.

Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62: 233–247.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, et al. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 2015; 15: 138. doi: 10.1186/s12885-015-1121-4.

Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014; 2014: 469251. doi: 10.1155/2014/469251.

Beith J, Burslem K, Bell R, Woodward N, McCarthy N, et al. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. Asia Pac J Clin Oncol 2016; 12: 3–18. doi: 10.1111/ajco.12491.

Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014; 32(29): 3307–3329. doi: 10.1200/JCO.2014.56.7479.

Rugo HS, Rumble RB, Burstein HJ. Endocrine therapy for hormone receptor positive metastatic breast cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract 2016; 12(6): 583–587. doi: 10.1200/JOP.2016.012914.

Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; (2): CD002747. doi: 10.1002/14651858.CD002747.

Robertson JF, Paridaens R, Bogaerts J, Rukazenkov Y, Campbell C, et al. Abstract P1-13-02: Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases. Cancer Research 2015; 75(9). doi: 10.1158/1538-7445.

Denduluri N, Somerfield MR, Eisen A, Holloway J, Hurria A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology Guideline adaptation of the Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol 2016; 34: 2416–2427.

Kümler I, Knoop AS, Jessing CA, Ejlertsen B, Nielsen DL. Review of hormone-based treatments in postmenopausal patients with advanced breast cancerfocusing on aromatase inhibitors and fulvestrant. ESMO Open 2016; 1(4): e000062. doi: 10.1136/esmoopen-2016-000062.

Litherland S, Jackson IM. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 1988; 15: 183–194.

Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988; 27: 721–728.

Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513–529.

Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol 1989; 7: 803–815.

Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, et al. Tamoxifen versus high-dose medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study. J Clin Oncol 1994; 12: 1630–1638.

Chi F, Wu R, Zeng Y, Xing R, Liu Y, et al. Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis. Breast Cancer 2013; 20: 111–122.

Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30: 2718–2724.

Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003; 30: 3–11.

Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19(10): 2596–2606. doi: 10.1200/JCO.2001.19.10.2596.

Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21(11): 2101–2109. doi: 10.1200/JCO.2003.04.194.

Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausalwomen: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748–3757.

Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758–3767.

Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92(9): 2247–2258.

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breastcancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26: 4883–4890.

Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006; 98: 1285–1291.

Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, et al. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat 2013; 139: 441–451.

Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol 1987; 112: R7–R10.

Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867–3873.

Fawell SE, White R, Hoare S, Sydenham M, Page M, et al. Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990; 87: 6883–6887.

Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106: 1377–1388.

Robertson JF. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data. Br J Cancer 2001; 85: 11–14. doi: 10.1054/bjoc.2001.1982.

Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogenreceptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol 2003; 17(3): 356–365. doi: 10.1210/me.2002-0323.

Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausalwomen previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22(9): 1605–1613. doi: 10.1200/JCO.2004.02.112.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28(30): 4594–4600. doi: 10.1200/JCO.2010.28.8415.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014; 106(1): djt337. doi: 10.1093/jnci/djt337.

Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: Results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat 2012; 133(1): 237–246. doi: 10.1007/s10549-011-1947-7.

Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, et al. A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer 2014; 14(6): 381–389. doi: 10.1016/j.clbc.2014.06.005.

Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breastcancer: Results from the FIRST study. J Clin Oncol 2009; 27(27): 4530–4535. doi: 10.1200/JCO.2008.21.1136.

Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012; 136(2): 503–511. doi: 10.1007/s10549-012-2192-4.

Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. J Clin Oncol 2015; 33(32): 3781–3787. doi: 10.1200/JCO.2015.61.5831.

Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial. Lancet 2016; 388(10063): 2997–3005. doi: 10.1016/S0140-6736(16)32389-3.

Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, et al. FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 30(16): 1919–1925. doi: 10.1200/JCO.2011.38.1095.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367(5): 435–444. doi: 10.1056/NEJMoa1201622.

Gampenrieder SP, Rinnerthaler G, Greil R. CDK4/6 inhibition in luminal breast cancer. Memo 2016; 9: 76–81. doi: 10.1007/s12254-016-0268-2.

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015; 16(1): 25–35. doi: 10.1016/S1470-2045(14)71159-3.

Finn RS, Martin M, Rugo HS, Jones, S, Im SA, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375(20): 1925–1936. doi: 10.1056/NEJMoa1607303.

Hortobagyi GN, Stemmer SM, Burris HA, Yap, YS, Sonke GS, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375(18): 1738–1748. doi: 10.1056/NEJMoa1609709.

Ribociclib receives EU approval as first-Line treatment for HR-positive, HER2-negative locally advanced or metastatic breast cancer. Available from: http://www.esmo.org/Oncology-News/Ribociclib-Receives-EU-Approval-as-First-Line-Treatment-for-HR-positive-HER2-negative-Locally-Advanced-or-Metastatic-Breast-Cancer.

Ribociclib (Kisqali). Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm546438.htm.

Goetz MP, Toi M, Klise S, Frenzel M, Bourayou N, Leo AD. MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2- locoregionally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2015; 33(suppl; abstr TPS624).

Di Leo A. ESMO 2017: Combined abemaciclib with NSAI show significant clinical benefit as initial treatment for patients with HR-positive/HER2-negative ABC at interim analysis. 2017. Available from: http://www.esmo.org/Oncology-News/Combined-Abemaciclib-with-NSAI-Show-Significant-Clinical-Benefit-as-Initial-Treatment-for-Patients-with-HR-positive-HER2-negative-ABC-at-Interim-Analysis.

Sahebjam S, Le Rhun E, Kulanthaivel P, Yurner PK, Klise S, et al. Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer. J Clin Oncol Abstract 2016; 526.

de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LC, et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs 2015; 33(5): 1012–1019. doi: 10.1007/s10637-015-0266-y.

Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, et al. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014; 15(12): 23024–23041. doi: 10.3390/ijms151223024.

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, et al. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol 2016; 34(220: 2602–2609. doi: 10.1200/JCO.2015.66.1595.

Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 2015; 33(9): 1045–1052. doi: 10.1200/JCO.2014.57.2388.

Rudloff J, Boulay A, Zumstein-Mecker S, Evans DB, O’Reilly T, et al. The mTOR pathway in estrogen response: A potential for a combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast carcinoma. Cancer Res 2004; 64: 1298.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10(23): 8059–8067. doi: 10.1158/1078-0432.CCR-04-0035.

Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, et al. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat 2014; 143(3): 459–467. doi: 10.1007/s10549-013-2814-5.

Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006; 24(7): 1052–1056. doi: 10.1200/JCO.2005.04.1053.

McKeage K, Curran MP, Plosker GL. Fulvestrant: A review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs 2004; 64(6): 633–648.

Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat 2005; 93: S11–S18. doi: 10.1007/s10549-005-9037-3.

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 2015; 12(10): 573–583. doi: 10.1038/nrclinonc.2015.117.

Angus L, Beije N, Jager A, Martens JW, Sleijfer S. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancerpatients. Cancer Treat Rev 2017; 52: 33–40. doi: 10.1016/j.ctrv.2016.11.001.

Chandarlapaty S, Chen D, He W, Sung P, Samoila A, et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2016; 2(10): 1310–1315. doi: 10.1001/jamaoncol.2016.1279.

Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol 2016; 34(25): 2961–2968. doi: 10.1200/JCO.2016.67.3061.

Watkins SM. The value of high dose tamoxifen in postmenopausal breast cancer patients progressing on standard doses: A pilot study. Br J Cancer 1988; 57(3): 320–321.

Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18(7): 1399–1411. doi: 10.1200/JCO.2000.18.7.1399.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after priornonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26(10): 1664–1670. doi: 10.1200/JCO.2007.13.5822.

Xu B, Jiang Z, Shao Z, Wang J, Feng J, et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: Results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 2011; 67(1): 223–230. doi: 10.1007/s00280-010-1483-x.

Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20(16): 3396–3403. doi: 10.1200/JCO.2002.10.057.

Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versusanastrozole in postmenopausal women with advanced breast cancer progressing on priorendocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20(16):3386–3395. doi: 10.1200/JCO.2002.10.058.

Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausalwomen: A prospective combined analysis of two multicenter trials. Cancer 2003; 98(2): 229–238. doi: 10.1002/cncr.11468.

Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidalaromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013; 14(10): 989–998. doi: 10.1016/S1470-2045(13)70322-X.

Turner NC, Huang Bartlett C, Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373: 1672–1673.

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17(4): 425–439. doi: 10.1016/S1470-2045(15)00613-0.

Fasching PA, Jerusalem GHM, Pivot X, Martin M, Laurentiis MD, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor- positive (HR+), human epidermal growth factor receptor 2- negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA- 3. J Clin Oncol 2016; 34 (suppl; abstr TPS624).

Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35(25): 2875-2884. doi: 10.1200/JCO.2017.73.7585.

Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520–529.

Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013; 30(10): 870–884. doi: 10.1007/s12325-013-0060-1.

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 2014; 25: 2357–2362.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650): 924 –926. doi: 10.1136/bmj.39489.470347.AD.

Faslodex receives EU approval as first-line therapy for advanced breast cancer. Available from: https://www.astrazeneca.com/media-centre/press-releases/2017/faslodex-receives-eu-approval-as-first-line-therapy-for-advanced-breast-cancer-26072017.html.

Fulvestrant prescribing information. Revised Aug 2017. Available from: https://www.azpicentral.com/faslodex/faslodex.pdf#page=1.




DOI: http://dx.doi.org/10.30564/amor.v4i1.171

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Ahmad Radzi, Fabian Wei Luen Lee

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.